ArticleAAPS PharmSciTech2026
Mitigating the Resolution-Field of View Trade-Off for Comprehensive Microstructural Characterization with Advanced AI Methods.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microstructural characterization of pharmaceutical drug products is essential for understanding process-microstructure-performance relationships and ensuring consistent product quality. However, quantitative characterization is limited by a trade-off between imaging resolution and field of view: high-resolution imaging captures fine structural detail but over small sample volumes, whereas lower-resolution imaging provides broader coverage while missing critical morphological features. To address this limitation, we developed and validated an integrated framework combining convolutional neural network (CNN)-based super-resolution with Generative Adversarial Network (GAN)-based microstructure synthesis. Lyophilized drug products imaged by X-ray microscopy at multiple resolutions served as the model system. We first demonstrated that imaging resolution is a governing factor in quantitative microstructural analysis: mean pore size showed a coefficient of variation of 40.2% across resolution levels, compared with only 0.47% attributable to spatial heterogeneity within the same sample. CNN-based upscaling using ESRGAN/BSRGAN recovered solid-wall structures and pore-size distributions lost after downsampling and restored effective diffusivity toward values measured in the original high-resolution data. In an independent validation using a separate formulation imaged at 5 and 10 µm per voxel, the upscaled images reproduced pore-size distributions and diffusivity profiles closer to the 5 µm reference and showed better recovery of CQA-relevant structural features than conventional bicubic interpolation, despite lower pixel-level image fidelity scores. GAN-based synthesis expanded the field of view four-fold from a small high-resolution seed region while preserving pore-size distributions and transport properties. Together, these findings demonstrate a scalable approach for improving microstructural characterization under practical imaging constraints.
Indexed as
Identifiers
42811251What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.